Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.

@article{Takada2004CytochromePP,
  title={Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.},
  author={Kazuki Takada and Million Arefayene and Zeruesenay Desta and Cheryl H Yarboro and Dimitrios T. Boumpas and James E. Balow and David A. Flockhart and Gabor G. Illei},
  journal={Arthritis and rheumatism},
  year={2004},
  volume={50 7},
  pages={2202-10}
}
OBJECTIVE Pulse cyclophosphamide is the treatment of choice for severe lupus nephritis. However, not all patients respond to this therapy, and gonadal toxicity is of particular concern. Cyclophosphamide is a prodrug that requires activation by cytochrome P450 (CYP) enzymes. We conducted a retrospective cohort study to test whether genetic polymorphisms of these enzymes are associated with the toxicity of, and clinical response to, cyclophosphamide in patients with lupus nephritis. METHODS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

Similar Papers

Loading similar papers…